United Kingdom

Adaptimmune Therapeutics Q3 loss per share $0.00

Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Adaptimmune Therapeutics Plc :Adaptimmune reports third quarter 2017 financial results and business updates.Q3 revenue $27.2 million versus $2.4 million.Q3 revenue view $6.3 million -- Thomson Reuters I/B/E/S.Q3 loss per share $0.00.Adaptimmune- existing cash, cash equivalents, securities, income from GSK on transition of NY-ESO program to fund operating plan through to early 2020​. 

Company Quote

-4.44089E-16 -0.00%
23 May 2019